Day: November 24, 2021

LISLE, Ill., Nov. 24, 2021 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS) announced today that Kieran O’Sullivan, President and Chief Executive Officer will be participating in a fireside chat at the Stephens 23rd Annual Investment Conference on December 2, 2021, at 3:00 p.m. (CST) in Nashville, TN. You may access a live webcast of the event using this link or from the Investors section of the CTS Corporation website at www.ctscorp.com. The webcast will also be available for replay on this website for 90 days following the presentation. About CTSCTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, and provides engineered products to customers in the aerospace/defense, industrial,...

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) — Legato Merger Corp. II (the “Company”) announced today that it closed its upsized initial public offering of 24,000,000 units at $10.00 per unit. The units are listed on the Nasdaq Global Market (“Nasdaq”) and began trading on November 22, 2021 under the ticker symbol “LGTOU”. Each unit consists of one share of common stock and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the common stock and redeemable warrants are expected to be listed on Nasdaq under the symbols “LGTO” and “LGTOW,” respectively.  Legato Merger Corp. II is a Delaware...

BEVERLY, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing, today announced it intends to pursue both 510k clearance and CLIA-waiver from the FDA to utilize the full potential of the MiQLab System™ for syndromic testing at the point of care. Syndromic testing allows medical providers to simultaneously test patient specimens for multiple pathogens that produce overlapping signs and symptoms. MiQLab’s broad multiplexing provides this capability and also allows for testing other clinically important markers such as antimicrobial resistance genes. Antimicrobial resistance is widely considered to be the next global pandemic.1 Scientists estimate that drug resistant...

Company AnnouncementHørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the Board of Directors of Allarity has exercised the authorization granted by the shareholders at the Extraordinary General Meeting held on November 22, 2021, to issue new warrants. The Board has resolved to grant a total of 51,292,653 warrants as a part of a new incentive program for the Board of Directors, employees and consultants in Allarity. All warrants are issued free of charge and are issued to ensure alignment of interests between the Company’s employees, management, Board of Directors, and shareholders as the Company completes its recapitalization, restructuring, and migration to the U.S. Nasdaq stock market. The 51,292,653 warrants to employees, consultants and board...

Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) — Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations.  As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory...

Press releaseParis, 24 November 2021 Communiqué from the Board of Directors of Orange Following the verdict reached by the Paris Appeal Court, the Orange group’s Board of Directors met today and took note of Stéphane Richard’s decision to hand over his mandate as Chairman and CEO. The Board has accepted his resignation. This will take effect once the new governance structure has been appointed and at the latest by 31 January 2022. Stéphane Richard will continue in his role until this date. The Board of Directors wishes to underline Stéphane Richard’s desire to ensure that the Group’s governance is preserved. The Board thanks him for his commitment at the helm of Orange for the past 11 years, from restoring an appeased working environment after the social crisis to the transformation of Orange into a leading multi-service operator...

Ten new members drawn from Canada’s First Nations, Inuit and Métis communities join Council The Council will provide advice and guidance to the board and CEO of CN on deepening its relationship with Indigenous peoples MONTREAL, Nov. 24, 2021 (GLOBE NEWSWIRE) — The co-chairs of CN’s (TSX: CNR) (NYSE: CNI) new Indigenous Advisory Council (“IAC”), Ms. Roberta Louise Jamieson, OC, Kanyen’kehà:ka, and the Hon. Murray Sinclair, C.C., M.S.M., Mizhana Geezhik, today announced the successful conclusion of their first meeting and its membership. The Council comprises accomplished and respected representatives of Canada’s First Nations, Inuit and Métis communities who will provide advice to CN’s Board and to the company’s President and Chief Executive Officer on issues that are relevant to CN’s relationship with the more than 200 Indigenous...